is semaglutide long acting LONG-ACTING INJECTION (SYH9017) OBTAINS CLINICAL TRIAL APPROVAL Manufacturer Frontiers | GLP−1 receptor agonists
Description
Metabolic Health Concerns
Retatrutide shows 28.7% weight loss vs 15% for Ozempic in trials
Therefore, it demonstrates significant efficacy in weight loss, blood sugar control, and cardiovascular protection, making it an important treatment option for type 2 diabetes patients and individuals managing their weight
